Business
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway
The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community. CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commerciali
About this update from Neuraxis, Inc.
[{"type":"image","alt":"NeurAxis, Inc.","displaySize":"","headline":null,"caption":"NeurAxis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/26D4nWOeQUW1.Tx0Xl.qeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355","width":300,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The new CPT code reflects the latest efficacious medical care available to patients, facilitating adoption and utilization.","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"The assignment of a Category I CPT® code demonstrates a strong message to payers, both commercial and government, that there is now a path to consistent reporting and reimbursement for providers in the medical community.","length":220,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":343,"olType":false},{"type":"text","content":"CARMEL, Ind., Jan. 08, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect, completing a successful commercial milestone for the Company.","length":435,"tagName":"p"},{"type":"text","content":"The assignment of the Category I CPT code is one of the most significant breakthroughs in efforts towards widespread adoption of IB-Stim®. This establishes a permanent, nationally recognized coding and billing pathway for NeurAxis’ PENFS therapy, reflecting broad clinical acceptance and meeting the American Medical Association’s (AMA) criteria for widespread utilization, clinical efficacy, and established standards of care.","length":427,"tagName":"p"},{"type":"text","content":"“Achieving this long-awaited milestone significantly strengthens the foundation of our business,” said Brian Carrico, Chief Executive Officer of NeurAxis. “With a Category I CPT code now in effect, we have greater commercial clarity due to a consistent and recognized code, improved payer alignment, and enhanced s...